These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34707005)

  • 41. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
    Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
    Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
    Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
    Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 44. Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study.
    Choi JY; Woen D; Jang SY; Lee H; Shin DS; Kwak Y; Lee H; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
    Front Oncol; 2023; 13():1230310. PubMed ID: 37849818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Go J; Ahn JH; Park JM; Choi SB; Kim JY; Park HS; Kim SI; Park BW; Park S
    Ann Surg Oncol; 2023 Nov; 30(12):7060-7068. PubMed ID: 37537485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
    Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
    [No Abstract]   [Full Text] [Related]  

  • 47. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
    Wang H; Huang Z; Xu B; Zhang J; He P; Gao F; Zhang R; Huang X; Shan M
    Clin Transl Oncol; 2024 Jun; 26(6):1467-1479. PubMed ID: 38190034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
    De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
    Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer.
    Zhang G; Xie W; Liu Z; Lin C; Piao Y; Xu L; Guo F; Xie X
    Tumori; 2014; 100(2):136-42. PubMed ID: 24852856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer.
    Wang P; Yue W; Li W; Luo Y; Li Z; Shao Y; He Z
    Cancer Manag Res; 2019; 11():813-819. PubMed ID: 30697073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prognostic significance of Ki-67 expression before and after neoadjuvant chemotherapy in different biological breast cancer phenotypes].
    Liu Y; Zhang X; Yu F; Liu J; Zhang M; Zhang S; Hao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):671-6. PubMed ID: 25564057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer.
    Hao Q; Dai L; Chang L; Song D; Liu D; Ma X; Wu H; Kang H
    Sci Rep; 2024 Aug; 14(1):18055. PubMed ID: 39103475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
    Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
    Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
    Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
    Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
    Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between the systemic immune-inflammation index and the efficacy of neoadjuvant chemotherapy, prognosis in HER2 positive breast cancer-a retrospective cohort study.
    Gu Q; Zhao J; Liu Y; Chen H; Wang L
    Gland Surg; 2023 May; 12(5):609-618. PubMed ID: 37284715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.